Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant lenvatinib + tislelizumab for high-risk clear cell renal cell carcinoma
ChiCTR2400093191Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in clear cell renal cell carcinoma (ccRCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: 1-year event-free survival and Operable rate after neoadjuvant lenvatinib plus tislelizumab. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2400093191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093191.